Snowden Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Snowden Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,598	Closed	-$293K	–	1261
2025 Q1	$293K	Buy	4,598 +73	+2%	+$7.68K	0.01%	992
2024 Q4	$550K	Sell	4,525 -2	-0%	-$245	0.02%	738
2024 Q3	$565K	Buy	4,527 +285	+7%	+$39.4K	0.02%	716
2024 Q2	$670K	Sell	4,242 -56	-1%	-$7.19K	0.02%	636
2024 Q1	$556K	Buy	4,298 +209	+5%	+$25.6K	0.02%	715
2023 Q4	$394K	Sell	4,089 -46	-1%	-$4.41K	0.02%	803
2023 Q3	$501K	Sell	4,135 -178	-4%	-$20.1K	0.02%	652
2023 Q2	$494K	Buy	+4,313	New	+$556K	0.02%	743
2022 Q1	–	Sell	-11	Closed	–	–	1936
2021 Q4	$0	Buy	+11	New	+$940	﹤0.01%	2144

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Snowden Capital Advisors's SRPT Position: Q2 2025 in Review

Snowden Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 4,598 shares — an estimated $293K sold.

Snowden Capital Advisors first reported a position in SRPT in Q4 2021 and held it in 9 quarters. The position peaked at $670K in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Snowden Capital Advisors reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Snowden Capital Advisors sold 4,598 Sarepta Therapeutics shares in Q2 2025, an estimated $293K.
Snowden Capital Advisors first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 9 quarters.
Snowden Capital Advisors's Sarepta Therapeutics position peaked at $670K in Q2 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Snowden Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.